In our recently concluded single-arm phase 2 immunotherapy clinical trial (NCT02853318) in recurrent OC patients, we safely combined anti-PD-1 pembrolizumab with anti-VEGF bevacizumab (to prevent new tumor vessel growth and enhance T cell infiltration into the TME)8 and oral cyclophosphamide (with the intent to deplete immunosuppressive regulatory T cells or Tregs)13,14. This evidence concerns the gene VEGFA and neoplasm.